Welcome!

Microsoft Cloud Authors: Janakiram MSV, Yeshim Deniz, David H Deans, Andreas Grabner, Stackify Blog

News Feed Item

Implant Sciences Reports Second Quarter Fiscal 2013 Financial Results

Company to Host Earnings Call on Thursday, January 31st at 4:15 PM EST

WILMINGTON, MA -- (Marketwire) -- 01/31/13 -- Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for the homeland security market and related industries, today announced financial results for the fiscal quarter and six months ended December 31, 2012.

Revenues for the second quarter ended December 31, 2012, increased 513%, to $6.9 million, from $1.1 million for the comparable prior year period. Our net loss for the quarter ended December 31, 2012 was $3.7 million as compared with a net loss of $3.3 million for the comparable prior year period, an increase of $0.4 million. The increase in the net loss is primarily due to $1.5 million of stock-based compensation recorded on the September 2012 officer and director option grants, increased operating expenses and increased interest expense.

Revenues for the six months ended December 31, 2012 increased 285%, to $8.4 million, from $2.2 million for the comparable prior year period. Our net loss for the six months ended December 31, 2012 was $16.5 million as compared with a net loss of $6.4 million for the comparable prior year period, an increase of $10.1 million. The increase in the net loss is primarily due to $10.8 million of stock-based compensation recorded on the September 2012 officer and director option grants, increased operating expenses and increased interest expense.

Glenn D. Bolduc, President and CEO of Implant Sciences, commented, "During our recently concluded second quarter, Implant Sciences achieved a number of important strategic goals that we believe position the Company for consistent sustainable growth. We have taken important steps to broaden the markets we serve, increase our revenue opportunities, and improve our financial stability. In addition, a number of officers and directors of the Company exercised stock options to purchase 876,000 of Implant Sciences' stock, clearly demonstrating our commitment to and belief in the Company." The following are some of our recent developments:

  • Our QS-B220 Benchtop Explosives and Narcotics Trace Detector successfully met the requirements for acceptance onto the Transportation Security Administration ("TSA") Air Cargo Screening Technology List, opening new markets for our products, domestically and internationally.
  • Completed the shipment with the India Ministry of Defence and received payment of $5.6 million in cash, which was applied to reduce accrued interest and borrowings under our credit facility with DMRJ Group, LLC.
  • Continued to increase our geographic distribution with sales to India, Asia, Africa, the Middle East and to several U.S. Government agencies. Increased diversification of markets served in the recently ended quarter to include; homeland security, corporate offices, airports, air cargo, transportation, nuclear plants, VIP protection and the petroleum industry.
  • Received several follow-on orders from existing customers around the world, demonstrating the reliability, operational and cost advantages of our technology.
  • Continue to attract industry experienced talent and enhanced our sales team and geographic coverage with the recruitment of an experienced sales manager, Natalya Hall, for the newly created position of Director of Sales for Russia and the Commonwealth of Independent States and strengthened our field service and training function with the addition of Mark Edgeworth. Ms. Hall was most recently with Bruker Corporation as Regional Sales Manager for the Southeast United States. Mr. Edgeworth was formerly the Applications Training manager for GE Homeland Protection (formerly GE Ion Track and Invision Technologies) and the Field Training Manager at GE Ion Track (formerly Ion Track Instruments).

Mr. Bolduc concluded, "TSA approval and delivery of the India Ministry of Defence order are very significant achievements which we believe establishes our credibility as the next generation explosives technology in the competitive global trace explosives industry. The influx of industry talent that we have recruited over the past twelve months provides a solid foundation from which to build upon as we work to innovate new products and technology, and grow our market share and revenues. We have much work ahead of ourselves, but remain excited about our future prospects."

Details for the quarter ended December 31, 2012 follow below.

Quarter Ended December 31, 2012 vs. December 31, 2011

  • Revenues for the quarter ended December 31, 2012 were $6,938,000 as compared with $1,132,000 for the comparable prior year period, an increase of $5,806,000, or 512.9%. The increase in revenue is due primarily to the shipment of the India Ministry of Defence order, resulting in a 511% increase in the number of QS-H150 handheld units sold and increased sales of parts and supplies during the quarter ended December 31, 2012, as compared to the comparable prior year period and, to a lesser extent, incremental sales of our QS-B220 benchtop units, which we began shipping commercially in the third quarter of fiscal 2012, partially offset by a 9.3% decrease in average unit sell prices on sales our QS-H150 handheld units.

  • Gross margin for the quarter ended December 31, 2012 was $2,468,000 or 35.5% of revenues as compared with gross margin of $365,000, or 32.2% of revenues for the comparable prior year period. The gross margin increase is primarily the higher unit volume of our explosives detection products sold, resulting in decreased unabsorbed manufacturing overhead and higher margins realized on sales of parts and supplies, partially offset by stock-based compensation recorded on the September 2012 officer and director option grants and by the 9.3% decrease in the average unit sell prices on sales of our QS-H150 handheld units in the quarter ended December 31, 2012, as compared to the comparable prior year period.

  • Research and development expense for the quarter ended December 31, 2012 was $1,068,000 as compared with $747,000 for the comparable prior year period, an increase of $321,000 or 43.0%. The increase in research and development expense is due primarily to increased payroll and related benefit costs, stock-based compensation recorded on the September 2012 officer and director option grants, partially offset by decreased contracted engineering.

  • Selling, general and administrative expenses for the quarter ended December 31, 2012 were $3,793,000 as compared with $1,982,000 for the comparable prior year period, an increase of $1,811,000, or 91.4%. The increase in selling, general and administrative expenses is due primarily a $1,221,000 increase in stock-based compensation recorded on the September 2012 officer and director option grants, increased payroll, related benefit costs and travel expense resulting from the addition of sales personnel, the imposition of liquidated damages of $298,000 under our contact with the India Ministry of Defence, due to delayed shipment and increased bank fees, partially offset by lower consulting fees due to the issuance of our common stock to certain consultants in the comparable prior year period.

  • For the quarter ended December 31, 2012, other expense, net was $1,330,000 as compared with other expense, net of $926,000, for the comparable prior year period, an increase of $404,000. The increase was primarily due to increased interest expense on higher borrowings under our credit facility with DMRJ. Interest expense increased $404,000 to $1,331,000 in the quarter ended December 31, 2012 from $927,000 in the comparable prior year period.

  • Our net loss for the quarter ended December 31, 2012 was $3,723,000 as compared with a net loss of $3,290,000 for the comparable prior year period, an increase of $433,000, or 13.2%. The increase in the net loss is primarily due to stock-based compensation recorded on the September 2012 officer and director option grants, increased operating expenses and increased interest expense.

Six Months Ended December 31, 2012 vs. December 31, 2011

  • Revenues for the six months ended December 31, 2012 were $8,353,000 as compared with $2,168,000 for the comparable prior year period, an increase of $6,185,000, or 285.3%. The increase in revenue is due primarily to the shipment of the India Ministry of Defence order, resulting in a 284% increase in the number of QS-H150 handheld units sold and increased sales of parts and supplies during the six months ended December 31, 2012, as compared to the comparable prior year period and, to a lesser extent, incremental sales of our QS-B220 benchtop units, which we began shipping commercially in the third quarter of fiscal 2012, partially offset by a 8.4% decrease in average unit sell prices on sales our QS-H150 handheld units.

  • Gross margin for the six months ended December 31, 2012 was $2,429,000 or 29.1% of revenues as compared with gross margin of $764,000 or 35.2% of revenues for the comparable prior year period. The decrease in gross margin is primarily the result of increased manufacturing overhead spending due to stock-based compensation recorded on the September 2012 officer and director option grants, increased manufacturing personnel costs and by the 8.4% decrease in the average unit sell prices on sales of our QS-H150 handheld units in the six months ended December 31, 2012, as compared to the comparable prior year period.

  • Research and development expense for the six months ended December 31, 2012 was $2,405,000 as compared with $1,566,000 for the comparable prior year period, an increase of $839,000 or 53.6%. The increase in research and development expense is due primarily to stock-based compensation recorded on the September 2012 officer and director option grants, increased payroll and related benefit costs, partially offset by decreased contracted engineering.

  • Selling, general and administrative expenses for the six months ended December 31, 2012 were $13,924,000 as compared with $3,795,000 for the comparable prior year period, an increase of $10,129,000, or 266.9%. The increase in selling, general and administrative expenses is due primarily to a $9,484,000 increase in stock-based compensation recorded on the September 2012 officer and director option grants, increased payroll, related benefit costs and travel expense resulting from the addition of sales personnel, the imposition of liquidated damages of $298,000 under our contact with the India Ministry of Defence, due to delayed shipment, increased legal fees and increased bank fees, partially offset by lower consulting fees due to the issuance of our common stock to certain consultants in the comparable prior year period.

  • For the six months ended December 31, 2012, other expense, net was $2,571,000 as compared with other income, net of $1,765,000, for the comparable prior year period, an increase of $806,000. The increase was primarily due to increased interest expense on higher borrowings under our credit facility with DMRJ. Interest expense increased $805,000 to $2,572,000 in the six months ended December 31, 2012 from $1,767,000 in the comparable prior year period.

  • Our net loss for the six months ended December 31, 2012 was $16,471,000 as compared with a net loss of $6,362,000 for the comparable prior year period, an increase of $10,109,000, or 158.9%. The increase in the net loss is primarily due to stock-based compensation recorded on the September 2012 officer and director option grants, increased operating expenses and increased interest expense.

Company Conference Call

Management will host a webcast and conference call on Thursday, January 31, 2013 at 4:15 PM Eastern time to review the Company's second quarter fiscal 2013 ended December 31, 2012 financial results. Following the Company's prepared remarks there will be a Q&A session. The call can be accessed by interested parties by dialing: 866-383-8119 within the U.S. or 617-597-5344 outside the U.S. and entering passcode 93095366. Participants are asked to call the assigned number approximately 5 minutes before the conference call begins. A replay of the conference call will be available approximately two hours after the call for one month by dialing: 888-286-8010 within the U.S. or 617-801-6888 outside the U.S. and entering passcode 48142954. The conference call will also be available live over the Internet at the investor relations section of Implant Sciences' website at www.implantsciences.com. A replay of the webcast will be available for one month after the call.

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by March 31, 2013; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; the risk that liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; the risks that we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others: and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

For further information, you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended June 30, 2012. The Company assumes no obligation to update the information contained in this press release.

                        Implant Sciences Corporation
                   Condensed Consolidated Balance Sheets

                                                December 31,     June 30,
                                                    2012           2012
                                                (Unaudited)     (Audited)
                                               -------------  -------------
ASSETS
Current assets:
  Cash and cash equivalents                    $      34,000  $      84,000
  Restricted cash and investments                  1,495,000      1,274,000
  Accounts receivable-trade, net of allowances
   of $21,000 and $20,000, respectively              515,000        182,000
  Inventories, net                                 1,469,000      3,193,000
  Prepaid expenses and other current assets          508,000        809,000
                                               -------------  -------------
    Total current assets                           4,021,000      5,542,000
Property and equipment, net                          231,000        220,000
Restricted cash and investments                      312,000        312,000
Other non-current assets                             112,000        162,000
                                               -------------  -------------
      Total assets                             $   4,676,000  $   6,236,000
                                               =============  =============
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
  Senior secured convertible promissory note   $   3,184,000  $   3,224,000
  Second senior secured convertible promissory
   note                                           12,000,000              -
  Senior secured promissory note                   1,000,000      1,000,000
  Line of credit                                  17,635,000     26,231,000
  Current maturities of obligations under
   capital lease                                      28,000         24,000
  Payable to Med-Tec                                  25,000         30,000
  Accrued expenses                                 5,258,000      4,360,000
  Accounts payable                                 2,693,000      2,654,000
  Deferred revenue                                   349,000      1,081,000
                                               -------------  -------------
    Total current liabilities                     42,172,000     38,604,000
Long-term liabilities:
  Long-term obligations under capital lease,
   net of current maturities                           6,000         33,000
                                               -------------  -------------
    Total long-term liabilities                        6,000         33,000
                                               -------------  -------------
      Total liabilities                           42,178,000     38,637,000
                                               -------------  -------------
Commitments and contingencies:
Series H Convertible Preferred Stock, no
 stated value; 15,000 shares authorized, no
 shares issued and outstanding                             -              -
                                               -------------  -------------
Stockholders' deficit:
  Common stock; $0.10 par value; 50,000,000
   shares authorized; 46,268,306 and46,257,761
   at December 31, 2012 and 39,163,540 and
   39,152,995 at June 30, 2012 shares issued
   and outstanding, respectively                   4,627,000      3,916,000
  Preferred stock; no stated value; 5,000,000
   shares authorized Series G Convertible
   Preferred Stock, no stated value; 650,000
   shares authorized, 111,667 shares issued
   and outstanding at December 31, 2012 and
   164,667 shares issued and outstanding at
   June 30, 2012, respectively (liquidation
   value $893,000 and $1,317,000,
   respectively)                                     186,000        274,000
  Additional paid-in capital                      94,108,000     83,436,000
  Accumulated deficit                           (135,993,000)  (119,522,000)
  Deferred compensation                             (357,000)      (432,000)
  Treasury stock, 10,545 common shares, at
   cost                                              (73,000)       (73,000)
                                               -------------  -------------
    Total stockholders' deficit                  (37,502,000)   (32,401,000)
                                               -------------  -------------
      Total liabilities and stockholders'
       deficit                                 $   4,676,000  $   6,236,000
                                               =============  =============



                        Implant Sciences Corporation
              Condensed Consolidated Statements of Operations
                                (Unaudited)

                     For the Three Months Ended   For the Six Months Ended
                            December 31,                December 31,
                     --------------------------  --------------------------
                         2012          2011          2012          2011
                     ------------  ------------  ------------  ------------
Revenues             $  6,938,000  $  1,132,000  $  8,353,000  $  2,168,000
Cost of revenues        4,470,000       767,000     5,924,000     1,404,000
                     ------------  ------------  ------------  ------------
  Gross margin          2,468,000       365,000     2,429,000       764,000
                     ------------  ------------  ------------  ------------
Operating expenses:
  Research and
   development          1,068,000       747,000     2,405,000     1,566,000
  Selling, general
   and
   administrative       3,793,000     1,982,000    13,924,000     3,795,000
                     ------------  ------------  ------------  ------------
    Total operating
     expenses           4,861,000     2,729,000    16,329,000     5,361,000
                     ------------  ------------  ------------  ------------
Loss from operations   (2,393,000)   (2,364,000)  (13,900,000)   (4,597,000)
                     ------------  ------------  ------------  ------------
Other income
 (expense), net:
  Interest income           1,000         1,000         1,000         2,000
  Interest expense     (1,331,000)     (927,000)   (2,572,000)   (1,767,000)
                     ------------  ------------  ------------  ------------
Total other income
 (expense), net        (1,330,000)     (926,000)   (2,571,000)   (1,765,000)
                     ------------  ------------  ------------  ------------
Net loss             $ (3,723,000) $ (3,290,000) $(16,471,000) $ (6,362,000)
                     ============  ============  ============  ============


Net loss per share,
 basic and diluted   $      (0.08) $      (0.10) $      (0.38) $      (0.20)
                     ============  ============  ============  ============
Weighted average
 shares used in
 computing net loss
 per common share,
 basic and diluted     45,465,728    33,061,330    43,222,973    32,505,774
                     ============  ============  ============  ============

Add to Digg Bookmark with del.icio.us Add to Newsvine

For further information contact:
Implant Sciences Corporation
Glenn Bolduc
President and CEO
(978) 752-1700
Email Contact

or

Investor Contact:
Laurel Moody
646-810-0608
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

@ThingsExpo Stories
SYS-CON Events announced today that IBM has been named “Diamond Sponsor” of SYS-CON's 21st Cloud Expo, which will take place on October 31 through November 2nd 2017 at the Santa Clara Convention Center in Santa Clara, California.
Infoblox delivers Actionable Network Intelligence to enterprise, government, and service provider customers around the world. They are the industry leader in DNS, DHCP, and IP address management, the category known as DDI. We empower thousands of organizations to control and secure their networks from the core-enabling them to increase efficiency and visibility, improve customer service, and meet compliance requirements.
SYS-CON Events announced today that TidalScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. TidalScale is the leading provider of Software-Defined Servers that bring flexibility to modern data centers by right-sizing servers on the fly to fit any data set or workload. TidalScale’s award-winning inverse hypervisor technology combines multiple commodity servers (including their ass...
As hybrid cloud becomes the de-facto standard mode of operation for most enterprises, new challenges arise on how to efficiently and economically share data across environments. In his session at 21st Cloud Expo, Dr. Allon Cohen, VP of Product at Elastifile, will explore new techniques and best practices that help enterprise IT benefit from the advantages of hybrid cloud environments by enabling data availability for both legacy enterprise and cloud-native mission critical applications. By rev...
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant tha...
As popularity of the smart home is growing and continues to go mainstream, technological factors play a greater role. The IoT protocol houses the interoperability battery consumption, security, and configuration of a smart home device, and it can be difficult for companies to choose the right kind for their product. For both DIY and professionally installed smart homes, developers need to consider each of these elements for their product to be successful in the market and current smart homes.
In his Opening Keynote at 21st Cloud Expo, John Considine, General Manager of IBM Cloud Infrastructure, will lead you through the exciting evolution of the cloud. He'll look at this major disruption from the perspective of technology, business models, and what this means for enterprises of all sizes. John Considine is General Manager of Cloud Infrastructure Services at IBM. In that role he is responsible for leading IBM’s public cloud infrastructure including strategy, development, and offering ...
SYS-CON Events announced today that N3N will exhibit at SYS-CON's @ThingsExpo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. N3N’s solutions increase the effectiveness of operations and control centers, increase the value of IoT investments, and facilitate real-time operational decision making. N3N enables operations teams with a four dimensional digital “big board” that consolidates real-time live video feeds alongside IoT sensor data a...
In a recent survey, Sumo Logic surveyed 1,500 customers who employ cloud services such as Amazon Web Services (AWS), Microsoft Azure, and Google Cloud Platform (GCP). According to the survey, a quarter of the respondents have already deployed Docker containers and nearly as many (23 percent) are employing the AWS Lambda serverless computing framework. It’s clear: serverless is here to stay. The adoption does come with some needed changes, within both application development and operations. Tha...
SYS-CON Events announced today that Avere Systems, a leading provider of enterprise storage for the hybrid cloud, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere delivers a more modern architectural approach to storage that doesn't require the overprovisioning of storage capacity to achieve performance, overspending on expensive storage media for inactive data or the overbui...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that mruby Forum will exhibit at the Japan External Trade Organization (JETRO) Pavilion at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. mruby is the lightweight implementation of the Ruby language. We introduce mruby and the mruby IoT framework that enhances development productivity. For more information, visit http://forum.mruby.org/.
Digital transformation is changing the face of business. The IDC predicts that enterprises will commit to a massive new scale of digital transformation, to stake out leadership positions in the "digital transformation economy." Accordingly, attendees at the upcoming Cloud Expo | @ThingsExpo at the Santa Clara Convention Center in Santa Clara, CA, Oct 31-Nov 2, will find fresh new content in a new track called Enterprise Cloud & Digital Transformation.
SYS-CON Events announced today that NetApp has been named “Bronze Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. NetApp is the data authority for hybrid cloud. NetApp provides a full range of hybrid cloud data services that simplify management of applications and data across cloud and on-premises environments to accelerate digital transformation. Together with their partners, NetApp emp...
Smart cities have the potential to change our lives at so many levels for citizens: less pollution, reduced parking obstacles, better health, education and more energy savings. Real-time data streaming and the Internet of Things (IoT) possess the power to turn this vision into a reality. However, most organizations today are building their data infrastructure to focus solely on addressing immediate business needs vs. a platform capable of quickly adapting emerging technologies to address future ...
Amazon is pursuing new markets and disrupting industries at an incredible pace. Almost every industry seems to be in its crosshairs. Companies and industries that once thought they were safe are now worried about being “Amazoned.”. The new watch word should be “Be afraid. Be very afraid.” In his session 21st Cloud Expo, Chris Kocher, a co-founder of Grey Heron, will address questions such as: What new areas is Amazon disrupting? How are they doing this? Where are they likely to go? What are th...
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software. They hope to capture value from emerging technologies such as IoT, SDN, and AI. Ultimately, irrespective of the vertical, it is about deriving value from independent software applications participating in an ecosystem as one comprehensive solution. In his session at @ThingsExpo, Kausik Sridhar, founder and CTO of Pulzze Systems, will discuss how given the magnitude of today's applicati...
Join IBM November 1 at 21st Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA, and learn how IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Cognitive analysis impacts today’s systems with unparalleled ability that were previously available only to manned, back-end operations. Thanks to cloud processing, IBM Watson can bring cognitive services and AI to intelligent, unmanned systems. Imagine a robot vacuum that becomes your personal assistant th...
SYS-CON Events announced today that SkyScale will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. SkyScale is a world-class provider of cloud-based, ultra-fast multi-GPU hardware platforms for lease to customers desiring the fastest performance available as a service anywhere in the world. SkyScale builds, configures, and manages dedicated systems strategically located in maximum-security...
SYS-CON Events announced today that Avere Systems, a leading provider of hybrid cloud enablement solutions, will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Avere Systems was created by file systems experts determined to reinvent storage by changing the way enterprises thought about and bought storage resources. With decades of experience behind the company’s founders, Avere got its ...